-99m-TRODAT-1 SPECT

SPECT
-99m-TRODAT-1
1 2 3 1 1 1 2
1
2
3
-99m-TRODAT-1
(DAT)
SPECT (H/Y )
22 27 H/Y 1~4
-99m-TRODAT-1 2~3
SPECT ROI /
(ST/CB)
PD
-99m-
TRODAT-1
ST/CB
(dopamine transporter, DAT) PD
[2-5]
[6-8] -99m-TRODAT-1
(specific accumulation) (striatum)
DAT
PD
-99m-TRODAT-1
PD DAT SPECT
-99m-TRODAT-1
SPECT
PD H-
Y
-99m-TRODAT-1 SPECT
2001;14:97-101
(Parkinson’s disease, PD)
PD
(symptoms) (signs) (accuracy)
70~80% [1] -123 -11 -18
22 7 15 25~83
60 17
PD 27 7 20 53~79 64 7
PD 1984
[9] (1) 4 (
(postural instability))
2 (2) PD
(pyramidal tracts signs)
H-Y PD
H/Y-1 7 2 5 53~64 60 4
H/Y-2 6 60~74 67
5 H/Y-3 4 14 5 9 54~79
65 12
89 12 1 90 2 18 90 3 5
181
215004 (0086)512-8651740
(0086)512-8284303 jinchang@public1.sz.js.cn
-99m-TRODAT-1
TRODAT-1 ( TRODAT-1 200 µg)
-99m 1 ml (740~1110 MBq) 100 30

Wu J et al
-99m-TRODAT-1
radiochemical purity 90%
/ (80/20)
SPECT
KClO 4
600 mg 30
-99m-TRODAT-1 555~740 MBq 2~3
SPECT
Sophy Camera
DS-7 SPECT
(low energy
general collimator) (matrix) 64 64
360˚ 6˚ 1 (frame) 55
SPECT 24
(L-DOPA) PD
Figure 2. Regression analysis of the 99m Tc-TRODAT-1 binding
ratio (ST/CB) 2-3 h postinjection and age of the healthy
volunteers (n = 22)
(filter:butterworth 4/16; cut-off: 0.25;
order: 1.5) (transverse) (sagittal)
(coronal) 3 5 mm 4
(ST)
(CB) ROI 2 ST/CB
TRODAT-
1
-99m-TRODAT-1 SPECT
PD
(H/Y-1 )
H/Y-1
H/Y-2
DAT
(Figure 1A) PD
ST/CB
DAT
Figure 1. Dopamine transporter imaging with 99m Tc-TRO-
DAT-1 in (A) normal volunteer, and patients with
Parkinson’s disease (B) H/Y-1, (C) H/Y-3 and (D) H/Y-4
DAT
PD (H/Y-3 4 )
(Figure 1B~D)
/
(ST/CB) 1.49 0.17 1.52 0.18 1.51
0.17 Figure 2 ST/CB
PD
ST/CB , H/Y-1 (n = 7) 1.43
0.11 1.54 0.15 1.49 0.12
Ann Nucl Med Sci 2001;14:97-101 Vol. 14 No. 2 June 2001
98

-99m-TRODAT-1
Technetium-99m-TRODAT-1 in Parkinson’s disease
(P

Wu J et al
-99m-TRODAT-1 SPECT DAT
PD
PD
-99m-TRODAT-1 SPECT DAT
-99m SPECT
1. Hughes AJ. Clinicopathological aspects of Parkinson’s
disease. Eur Neurol 1997;38 Suppl 2:13-20.
2. Booij J, Tissingh G, Winogrodzka A, van Royen EA.
Imaging of the dopaminergic neurotransmission system
using single-photon emission tomography and positron
emission tomography in patients with parkinsonism. Eur
J Nucl Med 1999;26:171-182.
3. Garnett ES, Firnau G, Nahmias C. Dopamine visualized
in the basal ganglia of living man. Nature 1983;305:137-
138.
4. Innis RB, Seibyl JP, Scanley BE, et al. Single photon
emission computed tomographic imaging demonstrates
loss of striatal dopamine transporters in Parkinson disease.
Proc Natl Acad Sci U S A 1993;90:11965-11969.
5. Kim SE, Lee WY, Chi DY, et al. SPECT imaging of
dopamine transporter with [ 123 I]β-CIT: a potential clinical
tool in Parkinson’s disease. Korean J Nucl Med
1996;30:19-34.
6.
99m
Tc-TRODAT-1
1999;19:146-148
7. Dresel HJ, Kung MP, Plossl K, Meegalla SK, Kung HF.
Pharmacological effects of dopaminergic drugs on in
vivo binding of [ 99m Tc]TRODAT-1 to the central
dopamine transporters in rats. Eur J Nucl Med
1998;25:31-39.
8. Kung HF, Kim HJ, Kung MP, Meegalla SK, Plossl K, Lee
HK. Imaging of dopamine transporters in humans with
technetium-99m TRODAT-1 Eur J Nucl Med
1996;23:1527-1530.
9.
1985;18:255
10.Trupp M, Belluardo N, Funakoshi H, Ibanez CF.
Complementary and overlapping expression of glial cell
line-derived neurotrophic factor (GDNF), c-ret protooncogene,
and GDNF receptor-alpha indicates multiple
mechanisms of trophic actions in the adult rat CNS. J
Neurosci 1997;17:3554-3567.
11. Gash DM, Zhang Z, Gerhardt G. Neuroprotective and
neurorestorative properties of GDNF. Ann Neurol 1998
(3 Suppl 1):S121-125.
12. Lapchak PA, Miller PJ, Collins F, Jiao S. Glial cell linederived
neurotrophic factor attenuates behavioural
deficits and regulates nigrostriatal dopaminergic and
peptidergic markers in 6-hydroxydopamine-lesioned
adult rats: comparison of intraventricular and intranigral
delivery. Neuroscience 1997;78:61-72.
13. Koller WC. Neuroprotection for Parkinson’s disease. Ann
Neurol 1998;44 (3 Suppl 1):S155-159.
14.Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-
desmethylselegiline, a metabolite of selegiline [L-(-)-
deprenyl], protects mesencephalic dopamine neurons
from excitotoxicity in vitro. J Neurochem 1997;68:434-
436.
15. Tissingh G, Bergmans P, Booij J, et al. Drug-naive
patients with Parkinson’s disease in Hoehn and Yahr
stages I and II show a bilateral decrease in striatal
dopamine transporters as revealed by [ 123 I]beta-CIT
SPECT. J Neurol 1998;245:14-20.
Ann Nucl Med Sci 2001;14:97-101 Vol. 14 No. 2 June 2001
100

-99m-TRODAT-1
Technetium-99m-TRODAT-1 in Parkinson’s disease
Preliminary Clinical Application of Dopamine Transporter
Imaging with Technetium-99m-TRODAT-1 and
SPECT in Parkinson’s Disease
Jinchang Wu 1 , Weifeng Luo 2 , Ping Fang 3 , Zengli Liu 1 , Jun Tang 1 , Feng Wang 1 , Shiyao Bao 2
1
Nuclear Medicine Department, Second Hospital Affiliated to Suzhou University, China
2
Neurology Department, Second Hospital Affiliated to Suzhou University, China
3
National Laboratory of Nuclear Medicine, Jiangsu Institute of Nuclear Medicine, China
Objective: The aim of the present study was to evaluate the usefulness of 99m Tc-TRODAT-1 as an imaging agent for
measuring changes in transporter concentrations in Parkinson’s disease (PD) and correlate the findings to the
severity of the disease (Hoehn and Yahr scale, H/Y).
Methods: Twenty-two healthy volunteers and 27 patients with PD of H/Y stage I- IV were investigated. Acquisitions
were performed 2~3 h postinjection of 99m Tc-TRODAT-1. ROIs were drawn over the striatum and the cerebellum. The
ratios of striatum-to-cerebellum (ST/CB) were calculated.
Results: The striatal uptake of 99m Tc-TRODAT-1 showed a significant decrease in patients with PD in comparison
with healthy volunteers and the ST/CB ratios was closely related to the stage of PD.
Conclusion: The present study demonstrates that it is possible to visualize and quantify the changes of dopamine
transporters in striatum in PD patients using 99m Tc-TRODAT-1 and SPECT with good correlation to H/Y stage.
Key words: technetium-99m, SPECT, dopamine transporter, brain, Parkinson’s disease
Ann Nucl Med Sci 2001;14:97-101
Received 12/1/2000; revised 2/18/2001; accepted 3/5/2001.
For correspondence or reprints contact: Jinchang Wu, M.D., Ph.D., Department of Nuclear Medicine, Second Hospital Affiliated to Suzhou University, Suzhou 215004, P.R.
China. Tel: (0086)512-8651740 Fax: (0086)512-8284303 E-mail: jinchang@public1.sz.js.cn
2001;14:97-101 2001 6 14 2
101